MGX (Metagenomi Therapeutics) Total Liabilities: $59.17 Mil (As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.26
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Total Liabilities?

Metagenomi Therapeutics MGX +4.13% 10 Total Liabilities is $59.17 Mil as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Metagenomi Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $59.17 Mil.

Metagenomi Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($69.49 Mil) to Dec. 2025 ($62.51 Mil) and declined from Dec. 2025 ($62.51 Mil) to Mar. 2026 ($59.17 Mil).

Metagenomi Therapeutics's annual Total Liabilities declined from Dec. 2023 ($500.43 Mil) to Dec. 2024 ($89.74 Mil) and declined from Dec. 2024 ($89.74 Mil) to Dec. 2025 ($62.51 Mil).

Metagenomi Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Total Liabilities Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
174.54 488.91 500.43 89.74 62.51

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.21 76.45 69.49 62.51 59.17
MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Metagenomi Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.933+(34.632+1.953
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+2.989+0+0)
=62.51

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=221.103-158.596
=62.51

Metagenomi Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.499+(33.081+1.953
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1.635+0+0)
=59.17

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=196.953-137.785
=59.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $59.17 Mil mean?
Metagenomi Therapeutics (MGX) has a Total Liabilities of $59.17 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Total Liabilities too high?
Metagenomi Therapeutics' current Total Liabilities is $59.17 Mil. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Total Liabilities compare to KALA and HYPD?
Metagenomi Therapeutics' Total Liabilities of $59.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Total Liabilities is $59.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Total Liabilities of $59.17 Mil. The current Total Liabilities is $59.17 Mil. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Total Liabilities is $59.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price